Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Wakamoto Casts Off Glaucoma Hopeful on Safety Worries
September 11, 2019
- Daiichi Sankyo Presents Updated PI Data of ADCs DS-1062, U3-1402 for NSCLC
September 11, 2019
- 1st RNAi Therapy Onpattro Makes Japan Debut
September 10, 2019
- Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
September 10, 2019
- Japan Lung Cancer Market to Surge to 317.5 Billion Yen in 2027: Fuji Keizai
September 10, 2019
- Japan Ethical Drug Sales Zoom 7.0% in July: Crecon
September 9, 2019
- Shonan iPark Kicks Off Demonstration Experiment Seeking “Mibyo” Business Opportunities
September 9, 2019
- Meiji Seika’s Schizophrenia Treatment ME2112 Misses Primary Goal in Japan PIII Study
September 9, 2019
- EA Pharma Obtains Global Rights for Glycolipid Compound from National Neurology Center
September 9, 2019
- Takeda Launches US Recall of Natpara Parathyroid Hormone
September 9, 2019
- Lonsurf Gets European Nod for Gastric Cancer
September 9, 2019
- To Counter Latuda Patent Cliff, Sumitomo Dainippon Poised to Buy 5 “Vants” Companies from Roivant
September 9, 2019
- Labor Union Urges MSD Japan to Make Convincing Case on Job Cuts
September 6, 2019
- MHLW Lifts All-Case PMS Requirement for Pfizer’s Xeljanz for RA Treatment
September 6, 2019
- Keytruda Continues to Enjoy Top Title in August Sales Ranking: Encise
September 6, 2019
- Japan Pharma Market Likely to Shrivel 0.7% Annually in Next 5 Years: IQVIA
September 5, 2019
- Roche/Chugai’s Rozlytrek, AstraZeneca COPD Combos and More Hit Shelves
September 5, 2019
- Anges, Mitsubishi Tanabe to Launch Gene Therapy Collategene on Sept. 10
September 5, 2019
- Candesartan Generics OK'ed for Pediatric Use, Now Offer Full Indications
September 5, 2019
- Edoxaban/Clopidogrel Combo Shows Non-Inferiority against Warfarin Triplet in AF: Daiichi Sankyo
September 5, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…